HIV Infection
Conditions
Keywords
HIV, Cohort, Early HIV infection, Côte d'Ivoire, Disease progression
Brief summary
Set-up of a biobank for patients with an estimated date of infection seroconverters: store plasma and cells samples at initial contact and during follow-up for future analysis and analysis in international collaborative cohort seroconverters.
Interventions
None listed
Sponsors
ANRS, Emerging Infectious Diseases
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* patients included in the last Primo-CI ANRS 1220 protocol * All HIV infected individuals diagnosed during a blood donation with an estimated date of HIV seroconversion that will respect the following criteria: (i) age ≥18 (ii) HIV-1 or HIV-1+2 infected, (iii) HIV-seronegative at the preceding donation; (iv) who returned to the clinic to be informed of their HIV test result (v) with an HIV serology confirmed with two specific tests in two different laboratories (vi) who have never received ART for curative purpose * informed on study objectives and have a signed informed consent.
Exclusion criteria
* Patient living outside of Abidjan
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Natural history of HIV infection in Sub-Saharan Africa | 12 months after ART initiation | Plasmatic HIV viral load and CD4 measured every six months and incidence of morbidity events associated with AIDS |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Evolution of markers of HIV infection and immunity | 12 months after ART initiation | CD4 count, immune activation, plasma HIV-RNA intracellular, HIV-DNA |
| Viral genetic diversity description | Inclusion (J0) | biomolecular analysis of HIV-1 |
| Primary resistance to antiretroviral treatment | Inclusion (J0) | Frequency of primary resistance to antiretroviral treatment (genotyping) |
| Estimate the probability of disease progression after HIV seroconversion | 12 months after ART initiation | Disease progression will be estimated with CD4 cell loss and time from seroconversion to clinical AIDS, death and antiretroviral therapy initiation |
| Incidence of pregnancies | 12 months after ART initiation | Occurence of pregnancies |
| T lymphocytes activation and evolution in seroconverters | Inclusion | Define parameters of activation of T lymphocytes and their evolution since primo-infection among individuals recently infected in West Africa; Expression of markers CD38, HLA-DR, CD28 and CD127 on CD4 and CD8 T cells by flux cytometry |
| Metabolic and lipodystrophic disorders | 12 months after ART initiation | Metabolic analysis (Total Cholesterol, HDL and LDL, Triglycerides) and lipodystrophia measurements |
Countries
Côte d’Ivoire
Outcome results
None listed